NCT00411619 · OUTCOME

Overall Reduction in SEGA Tumor Volume.

Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex · Source last updated 2014-10-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Groups in this outcome

This was a non-randomized, open-label, single arm study; all patients in the study received treatment with everolimus.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Everolimus	26

# with reductions > 30% relative to baseline

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Everolimus	14	Not reported	Not reported	Not reported	Not reported

# with reductions > 50% relative to baseline

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Everolimus	12	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

groups

param Type

NUMBER

reporting Status

POSTED

time Frame

During the entire study

title

Overall Reduction in SEGA Tumor Volume.

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice